Eli Lilly

Icon and Bristol-Myers Squibb build on strategic partnership, extending it to early-phase work

Monday, September 5, 2011 08:00 AM

Icon and Bristol-Myers Squibb (BMS) have inked a preferred-provider agreement for early-phase development. This constitutes the CRO’s second sizable agreement with BMS; in June 2010, the two formed a strategic partnership, with Icon focused on providing global support for the drug developer’s clinical development pipeline.

More... »

Eli Lilly in talks with Turkish generic drug company

Friday, September 2, 2011 01:23 PM

Eli Lilly is in talks to form a partnership with, and potentially invest in, Turkish generic-drug company Mustafa Nevzat Ilac Sanayii (MN Pharmaceuticals), the Wall Street Journal reported, citing people familiar with the matter, according to Reuters.

More... »

American Cancer Society enrolls thousands in prevention study

Wednesday, August 24, 2011 11:33 AM

For the past two years, the American Cancer Society has been enrolling people across the country in its latest research project, cancer prevention study-3, according to a report in the Indianapolis Star. In the first week of October, eight of Indianapolis’ major employers will contribute, signing up people at their work sites.

More... »

FDA reviews BYDUREON, type 2 diabetes medication

Friday, August 12, 2011 02:48 PM

Amylin Pharmaceuticals, Eli Lilly, and Alkermes have reported that the FDA has acknowledged the companies’ BYDUREON (exenatide extended-release for injectable suspension) resubmission. The FDA has categorized it as a class II resubmission requiring up to six months for review and assigned a new Prescription Drug User Fee Act (PDUFA) action date of January 28, 2012. BYDUREON is an investigational medication for type 2 diabetes.

More... »

Omthera names Lloyd VP regulatory affairs

Monday, August 1, 2011 12:32 PM

Omthera Pharmaceuticals reports that Ramona M. Lloyd has joined the company as vice president regulatory affairs, effective immediately.  In this newly created position, Dr. Lloyd will be responsible for the management of all regulatory activities, including regulatory strategy and interactions with the FDA.

More... »

Icon acquires Firecrest Clinical, adding portal technology to boost site quality while reducing errors and costs

Monday, July 25, 2011 08:02 AM

As large pharmaceutical companies scrutinize the pack of mid- and top-tier CROs to determine who wins the coveted strategic-partnership agreements, there’s a mad scramble among CROs to differentiate themselves from one another and stand out as efficient, high quality, exciting and deserving.

More... »

Lilly releases Alzheimer’s research results

Wednesday, July 20, 2011 11:18 AM

Lily presented data from the first of two phase III trials of semagacestat, including data from a 32-week follow-up period after dosing was halted in August 2010.

More... »

Elan cuts 104 jobs

Friday, July 15, 2011 10:13 AM

Following the recent decision to sell its drug manufacturing unit to Alkermes for $960 million, Elan is eliminating 104 jobs from a Pennsylvania facility that is part of the deal, according to a notice filed with the Pennsylvania Department of Labor.

More... »

Novartis considers IPO in China

Wednesday, July 13, 2011 10:10 AM

Swiss drug maker Novartis is considering a possible initial public offering in China, joining a growing list of multinationals eyeing a listing on Shanghai's planned international board, two people with knowledge of the situation told Reuters.

More... »

FDA eases rules for Alzheimer’s experiments to speed new treatments for dementia

Tuesday, July 12, 2011 12:35 PM

The FDA is making it easier to test new Alzheimer’s drugs, hoping to speed progress toward new treatments for the mind-robbing disease, according to an Associated Press report.

More... »